

Emergent BioSolutions Inc.
Form 8-K
November 03, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 1, 2011

Emergent BioSolutions Inc.
(Exact Name of Registrant as Specified in Charter)

| | | |
|---------------------------------------------------------------|------------------------------------------|----------------------------------------------------|
| Delaware (State or Other Jurisdiction of Incorporation) | 001-33137 (Commission File Number) | 14-1902018 (IRS Employer Identification No.) |
|---------------------------------------------------------------|------------------------------------------|----------------------------------------------------|

| | |
|-----------------------------------------------------------------------------------------------------|---------------------|
| 2273 Research Boulevard, Suite 400, Rockville, Maryland (Address of Principal Executive Offices) | 20850 (Zip Code) |
|-----------------------------------------------------------------------------------------------------|---------------------|

Registrant's telephone number, including area code: (301) 795-1800

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01. Entry into a Material Definitive Agreement.

On November 1, 2011, Emergent BioSolutions Inc. (the “Company”) entered into an amendment (the “Amendment”) to a consulting services agreement dated effective April 1, 2011 with The Hauer Group (the “Consulting Services Agreement”). The Amendment provides for the termination of the Consulting Services Agreement effective at 5:00 p.m. on November 1, 2011. The terms of the Consulting Services Agreement were previously reported in the Company’s Current Report on Form 8-K dated April 6, 2011, which Form 8-K is incorporated by reference into this Item 1.01. The Company has no further liability to The Hauer Group as a result of the termination of the Consulting Services Agreement.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 3, 2011

EMERGENT BIOSOLUTIONS INC.

By:/s/Jay G. Reilly

Jay G. Reilly

General Counsel